TIDMCLIN

RNS Number : 1749M

Clinigen Group plc

12 October 2016

12 October 2016

Annual Report and Accounts and AGM

Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceuticals and services group, announces that its annual report and accounts for the year ended 30 June 2016 is now available on the Group's website at www.clinigengroup.com.

Copies of the Annual Report and Accounts will be posted to shareholders later today.

The Group will hold its Annual General Meeting ('AGM') on 11 November 2016 at 10.00am at Instinctif Partners' offices, 65 Gresham Street, London EC2V 7NQ. Shaun Chilton, Group Chief Executive Officer-designate, will give a presentation at the AGM. The slides will be made available on the Group's website after the meeting. No new material information will be provided.

- Ends -

Contact Details

 
 Clinigen Group plc                  Tel: +44 (0) 1283 
                                      495010 
 Peter George, Group Chief 
  Executive Officer 
  Shaun Chilton, Group Chief 
  Executive Officer-designate 
 Martin Abell, Group Chief 
  Financial Officer 
 
 Numis Securities Limited            Tel: +44 (0) 20 
                                      7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 
 Peel Hunt LLP - Joint Broker   Tel: +44 (0) 20 
                                 7418 8900 
 James Steel / Dr Christopher 
  Golden 
 
   Instinctif Partners            Tel: +44 (0) 20 
                                  7457 2020 
 Adrian Duffield / Melanie 
  Toyne-Sewell / Jayne Crook    Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSGBBDGLBBBGLB

(END) Dow Jones Newswires

October 12, 2016 02:00 ET (06:00 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Clinigen Charts.
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Clinigen Charts.